Macrophage migration inhibitory factor in inflammasome formation and macrophage recruitment by cervical squamous cell carcinoma cells

Zhang,Qianqian; Wang,Mengxin; Wu,Suhui

doi:10.3892/ol.2025.14910

Macrophage migration inhibitory factor in inflammasome formation and macrophage recruitment by cervical squamous cell carcinoma cells

Authors:
- Qianqian Zhang
- Mengxin Wang
- Suhui Wu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi 030032, P.R. China
Published online on: January 28, 2025 https://doi.org/10.3892/ol.2025.14910
Article Number: 164
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the demonstrated efficacy of immune checkpoint blockade therapies in various types of cancer, their efficacy in cervical cancer is limited. A crucial pro‑inflammatory cytokine, macrophage migration inhibitory factor (MIF), is highly expressed in various types of cancers and contributes to tumor progression via the regulation of inflammatory responses and the tumor microenvironment. The present study aimed to explore the role of MIF in cervical squamous cell carcinoma (CSCC). Western blotting, reverse transcription‑quantitative polymerase chain reaction, Cell‑Counting Kit‑8, flow cytometry and enzyme‑linked immunosorbent assays were used to investigate the effects of MIF on CSCC progression and in the formation of inflammasomes using SiHa cells. Transcriptome and proteome sequencing were combined to screen for key effector proteins of MIF. Moreover, in vitro co‑culture experiments were used to evaluate the roles of MIF and TSC22 domain family protein 3 (TSC22D3) as inflammatory tumor‑promoting factors in macrophage recruitment and polarization induction. The results indicated that MIF was highly expressed in CSCC with lymph node metastasis, positively associated with cervical cancer stage, and associated with a poor prognosis. MIF was also found to promote the progression of CSCC cells and to be associated with inflammasome activation. Multi‑omics screening results indicated that TSC22D3 may be an important MIF interacting factor. Moreover, MIF and TSC22D3 facilitated inflammasome activation, THP‑1 cell migration and M2 polarization. Therefore, it is suggested that MIF and TSC22D3 may induce macrophage infiltration in cervical cancer lesions and affect the tumor microenvironment by polarizing macrophages toward the M2 phenotype, thereby promoting CSCC progression. The present study highlights the potential of the MIF‑TSC22D3 axis as a novel therapeutic target, which could conceivably help to improve the efficacy of immunotherapy in the treatment of recurrent or metastatic cervical cancer.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Giaquinto AN and Jemal A: Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024. View Article : Google Scholar : PubMed/NCBI
4	Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
5	Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, et al: First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: Final overall survival results of KEYNOTE-826. J Clin Oncol. 41:5505–5511. 2023. View Article : Google Scholar : PubMed/NCBI
6	Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, et al: Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 24:392–402. 2023. View Article : Google Scholar : PubMed/NCBI
7	Kang I and Bucala R: The immunobiology of MIF: Function, genetics and prospects for precision medicine. Nat Rev Rheumatol. 15:427–437. 2019. View Article : Google Scholar : PubMed/NCBI
8	Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y and Li Y: Inflammation and tumor progression: Signaling pathways and targeted intervention. Signal Transduct Target Ther. 6:2632021. View Article : Google Scholar : PubMed/NCBI
9	Greten FR and Grivennikov SI: Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity. 51:27–41. 2019. View Article : Google Scholar : PubMed/NCBI
10	Ravichandran KA and Heneka MT: Inflammasomes in neurological disorders-mechanisms and therapeutic potential. Nat Rev Neurol. 20:67–83. 2024. View Article : Google Scholar : PubMed/NCBI
11	Fu J, Schroder K and Wu H: Mechanistic insights from inflammasome structures. Nat Rev Immunol. 24:518–535. 2024. View Article : Google Scholar : PubMed/NCBI
12	Harris J, VanPatten S, Deen NS, Al-Abed Y and Morand EF: Rediscovering MIF: New tricks for an old cytokine. Trends Immunol. 40:447–462. 2019. View Article : Google Scholar : PubMed/NCBI
13	Liu Y, Liu Y, Wang Q, Song Y, Chen S, Cheng B, Zhang Y, Cui Z, Wu Z and Zhu C: MIF inhibitor ISO-1 alleviates severe acute pancreatitis-associated acute kidney injury by suppressing the NLRP3 inflammasome signaling pathway. Int Immunopharmacol. 96:1075552021. View Article : Google Scholar : PubMed/NCBI
14	Wu S, Lian J, Tao H, Shang H and Zhang L: Correlation of macrophage migration inhibitory factor gene polymorphism with the risk of early-stage cervical cancer and lymphatic metastasis. Oncol Lett. 2:1261–1267. 2011. View Article : Google Scholar : PubMed/NCBI
15	Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T and Tada K: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 26:171–176. 1980. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Yang H, Xia L, Chen J, Zhang S, Martin V, Li Q, Lin S, Chen J, Calmette J, Lu M, et al: Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. Nat Med. 25:1428–1441. 2019. View Article : Google Scholar : PubMed/NCBI
18	Nataraja C, Flynn J, Dankers W, Northcott M, Zhu W, Sherlock R, Bennett TJ, Russ BE, Miceli I, Pervin M, et al: GILZ regulates type I interferon release and sequesters STAT1. J Autoimmun. 131:1028582022. View Article : Google Scholar : PubMed/NCBI
19	Flamini S, Sergeev P, Viana de Barros Z, Mello T, Biagioli M, Paglialunga M, Fiorucci C, Prikazchikova T, Pagano S, Gagliardi A, et al: Glucocorticoid-induced leucine zipper regulates liver fibrosis by suppressing CCL2-mediated leukocyte recruitment. Cell Death Dis. 12:4212021. View Article : Google Scholar : PubMed/NCBI
20	Ma Y, Yang H and Kroemer G: Endogenous and exogenous glucocorticoids abolish the efficacy of immune-dependent cancer therapies. Oncoimmunology. 9:16736352020. View Article : Google Scholar : PubMed/NCBI
21	de Visser KE and Joyce JA: The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI
22	Mellman I, Chen DS, Powles T and Turley SJ: The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 56:2188–2205. 2023. View Article : Google Scholar : PubMed/NCBI
23	Ochando J, Mulder WJM, Madsen JC, Netea MG and Duivenvoorden R: Trained immunity-basic concepts and contributions to immunopathology. Nat Rev Nephrol. 19:23–37. 2023. View Article : Google Scholar : PubMed/NCBI
24	Kloosterman DJ and Akkari L: Macrophages at the interface of the co-evolving cancer ecosystem. Cell. 186:1627–1651. 2023. View Article : Google Scholar : PubMed/NCBI
25	Pittet MJ, Michielin O and Migliorini D: Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 19:402–421. 2022. View Article : Google Scholar : PubMed/NCBI
26	Locati M, Curtale G and Mantovani A: Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 15:123–147. 2020. View Article : Google Scholar : PubMed/NCBI
27	Wang H, Yung MMH, Ngan HYS, Chan KKL and Chan DW: The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression. Int J Mol Sci. 22:65602021. View Article : Google Scholar : PubMed/NCBI
28	Anderson NR, Minutolo NG, Gill S and Klichinsky M: Macrophage-based approaches for cancer immunotherapy. Cancer Res. 81:1201–1208. 2021. View Article : Google Scholar : PubMed/NCBI
29	Bian Z, Gong Y, Huang T, Lee CZW, Bian L, Bai Z, Shi H, Zeng Y, Liu C, He J, et al: Deciphering human macrophage development at single-cell resolution. Nature. 582:571–576. 2020. View Article : Google Scholar : PubMed/NCBI
30	Woolbright BL, Rajendran G, Abbott E, Martin A, Amalraj S, Dennis K, Li X, Warrick J and Taylor JA III: Role of MIF1/MIF2/CD74 interactions in bladder cancer. J Pathol. 259:46–55. 2022. View Article : Google Scholar : PubMed/NCBI
31	Huang G, Ma L, Shen L, Lei Y, Guo L, Deng Y and Ding Y: MIF/SCL3A2 depletion inhibits the proliferation and metastasis of colorectal cancer cells via the AKT/GSK-3β pathway and cell iron death. J Cell Mol Med. 26:3410–3422. 2022. View Article : Google Scholar : PubMed/NCBI
32	Jia X, Xi J, Tian B, Zhang Y, Wang Z, Wang F, Li Z, Long J, Wang J, Fan GH and Li Q: The tautomerase activity of tumor exosomal MIF promotes pancreatic cancer progression by modulating MDSC differentiation. Cancer Immunol Res. 12:72–90. 2024. View Article : Google Scholar : PubMed/NCBI
33	Penticuff JC, Woolbright BL, Sielecki TM, Weir SJ and Taylor JA: MIF family proteins in genitourinary cancer: Tumorigenic roles and therapeutic potential. Nat Rev Urol. 16:318–328. 2019. View Article : Google Scholar : PubMed/NCBI
34	Wang Q, Wei Y and Zhang J: Combined knockdown of D-dopachrome tautomerase and migration inhibitory factor inhibits the proliferation, migration, and invasion in human cervical cancer. Int J Gynecol Cancer. 27:634–642. 2017. View Article : Google Scholar : PubMed/NCBI
35	Cao X and Xu J: Insights into inflammasome and its research advances in cancer. Tumori. 105:456–464. 2019. View Article : Google Scholar : PubMed/NCBI
36	Barnett KC, Li S, Liang K and Ting JPY: A 360° view of the inflammasome: Mechanisms of activation, cell death, and diseases. Cell. 186:2288–2312. 2023. View Article : Google Scholar : PubMed/NCBI
37	Ershaid N, Sharon Y, Doron H, Raz Y, Shani O, Cohen N, Monteran L, Leider-Trejo L, Ben-Shmuel A, Yassin M, et al: NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis. Nat Commun. 10:43752019. View Article : Google Scholar : PubMed/NCBI
38	Kopalli SR, Kang TB, Lee KH and Koppula S: NLRP3 Inflammasome activation inhibitors in inflammation-associated cancer immunotherapy: An update on the recent patents. Recent Pat Anticancer Drug Discov. 13:106–117. 2018. View Article : Google Scholar : PubMed/NCBI
39	Wang L, Wang C, Tao Z, Zhu W, Su Y and Choi WS: Tumor-associated macrophages facilitate oral squamous cell carcinomas migration and invasion by MIF/NLRP3/IL-1β circuit: A crosstalk interrupted by melatonin. Biochim Biophys Acta Mol Basis Dis. 1869:1666952023. View Article : Google Scholar : PubMed/NCBI
40	Basak U, Sarkar T, Mukherjee S, Chakraborty S, Dutta A, Dutta S, Nayak D, Kaushik S, Das T and Sa G: Tumor-associated macrophages: An effective player of the tumor microenvironment. Front Immunol. 14:12952572023. View Article : Google Scholar : PubMed/NCBI
41	Figueiredo CR, Azevedo RA, Mousdell S, Resende-Lara PT, Ireland L, Santos A, Girola N, Cunha RLOR, Schmid MC, Polonelli L, et al: Blockade of MIF-CD74 signalling on macrophages and dendritic cells restores the antitumour immune response against metastatic melanoma. Front Immunol. 9:11322018. View Article : Google Scholar : PubMed/NCBI
42	Perez-Riverol Y, Bai J, Bandla C, García-Seisdedos D, Hewapathirana S, Kamatchinathan S, Kundu DJ, Prakash A, Frericks-Zipper A, Eisenacher M, et al: The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50:D543–D552. 2022. View Article : Google Scholar : PubMed/NCBI